Skip to main content
Terug
MBX logo

MBX Biosciences, Inc. Common Stock

Datakwaliteit: 100%
MBX
NASDAQ Healthcare Biotechnology
€ 27,82
▼ € 0,32 (-1,14%)
Marktkapitalisatie: 934,56M
Dagbereik
€ 26,84 € 28,45
52-Weeksbereik
€ 4,81 € 44,89
Volume
368.182
50D / 200D Gem.
€ 35,10 / € 22,42
Vorige Slotkoers
€ 28,14

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -10,8 0,3
P/B 2,5 2,9
ROE % -27,8 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 55,33 +98.9%
Low: € 18,00 High: € 88,00
Forward WPA
-€ 2,85
Omzet Sch.
0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 -€ 1,61
-€ 1,61 – -€ 1,61
260 M 5
FY2029 -€ 3,09
-€ 3,09 – -€ 3,09
130 M 2
FY2028 -€ 4,44
-€ 5,85 – -€ 1,87
27 M 7

Belangrijkste Punten

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -81,88M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-27,76%
ROIC-19,89%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,00
Current Ratio24,62
Interest Coverage0,00

Waardering

P/E Ratio
-10,75
P/B Ratio2,53
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -86,97M
ROE -27,76% ROA -22,58%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -81,88M
ROIC -19,89% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 24,62
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -10,75 P/B Ratio 2,53
P/S Ratio N/A PEG Ratio -0,46
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 934,56M Enterprise Value 859,87M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue 0,0 0,0 0,0 0,0
Net Income -86,97M -61,92M -32,56M -26,14M
EPS (Diluted) -2,38 -1,85 -1,02 -0,82
Gross Profit -248.000,0 0,0 0,0 0,0
Operating Income -98,06M -68,19M -35,31M -25,16M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 385,14M 268,54M 84,18M 45,10M
Total Liabilities 15,92M 11,09M 156,65M 87,70M
Shareholders' Equity 369,22M 257,44M -72,47M -42,61M
Total Debt 596.000,0 171.000,0 324.000,0 461.000,0
Cash & Equivalents 75,29M 49,35M 30,52M 24,21M
Current Assets 381,54M 267,29M 83,47M 44,21M
Current Liabilities 15,50M 11,05M 3,93M 3,43M